Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Transition from stage C to stage D of heart failure (HF) represents an irreversible process toward end-stage disease. Crucial interventions to be adopted in the attempt to interfere with this process are represented by the identification of patients at high risk to develop HF progression and by an effective and prompt management. Markers of worse prognosis and disease progression are well established and include recurrence of HF decompensation, intolerance to the neurohormonal standard pharmacological treatment, and resistance to loop diuretics. In addition, both NT-proBNP and sympathetic nervous system (SNS) overdrive are strong predictors of adverse clinical outcome and allow to identify high-risk HF patients even in the presence of mild symptoms. To counteract the deleterious effects of the SNS activation, new strategies such as a new drug combining angiotensin receptor and neprilysin inhibition and baroreceptor stimulation therapy (BAT) have been investigated. Inability to properly counteract the SNS overdrive leads to acute HF decompensation by different mechanisms. The leading ones are represented by the progressive sodium and water retention with fluid overload and by the blood volume redistribution between splanchnic and non-splanchnic regions. The correct understanding of these mechanisms, together with the availability of new therapeutic options such as peritoneal ultrafiltration, represent the rationale but not infrequently overlooked therapeutic options to improve congestion management in HF patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Presently, studies have reported SGLT-2i can regulate the sympathetic system which can be found to be especially over-activated in heart failure,62,63”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [63]
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
Cleland, J. G. F., Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., & Tavazzi, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050496 · Cited by 6,276
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Mullens, W., Abrahams, Z., Francis, G. S., Sokos, G., Taylor, D. O., Starling, R. C., Young, J. B., & Tang, W. H. W. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.068 · Cited by 1,674
Cited by
Nguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97
Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics
Napoli, C., Benincasa, G., Donatelli, F., & Ambrosio, G. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.03.007 · Cited by 88
Self-citationGlucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
Gronda, E., Jessup, M. L., Iacoviello, M., Palazzuoli, A., & Napoli, C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018889 · Cited by 95
Self-citationNovel Insights Regarding Nitric Oxide and Cardiovascular Diseases
Infante, T., Costa, D., & Napoli, C. (2021) · Angiology · doi:10.1177/0003319720979243 · Cited by 75
“Heart failure is classically classified according to left ventricular ejection fraction (LVEF) percentage into HF with reduced EF (HFrEF) and HF with preserved EF (HFpEF).(91,92) Coronary heart disease (CHD) represents a major underlying cause of HF.”
BackgroundThe role of non-invasive devices for the telemonitoring of heart failure patients
Faragli, A., Abawi, D., Quinn, C., Cvetković, M., Schlabs, T., Tahirović, E., Düngen, H., Pieske, B. M., Kelle, S., Edelmann, F., et al. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09963-7 · Cited by 73
“When these patients are admitted to the hospital with body fluids congestion, high doses of diuretics are administered [33].”
Background
Metadata
- Authors
- Gronda, E., Vanoli, E., Sacchi, S., Grassi, G., Ambrosio, G., & Napoli, C.
- Affiliations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University of Pavia (IT)
- University of Milano-Bicocca (IT)
- University of Perugia (IT)
- Corresponding author
- Gronda, Edoardo
- Venue
- Heart Failure Reviews
- Published
- 2019-08-13
- Volume
- 25
- Issue
- 2
- Pages
- 295-303
- ISSN
- 1382-4147 (ISSN-L)
- 1573-7322
- OpenAlex
- W2967206555
- Cited by
- 30
- References
- 64
- Citations by year
- 2025: 4 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 9 · 2019: 1
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Heart Failure Reviews (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- heart failure progression, reduced ejection fraction, heart failure decompensation, NT-proBNP, angiotensin receptor-neprilysin inhibition, loop diuretic resistance, fluid overload, sodium and water retention, blood volume redistribution, peritoneal ultrafiltration, congestion management, end-stage heart failure, prognostic factors
- MeSH terms
- Heart Failure, Humans, Peptide Fragments, Risk Factors, Stroke Volume, Biomarkers, Disease Progression, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. https://app.cochat.ai/papers/10.1007/s10741-019-09823-z
- The paper
- Gronda, E., Vanoli, E., Sacchi, S., Grassi, G., Ambrosio, G., & Napoli, C. (2020). Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. Heart Failure Reviews. https://doi.org/10.1007/s10741-019-09823-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.